Skip to main content

Advertisement

Table 2 Univariate and multivariate analysis for progression-free survival to first-generation TKI therapy

From: First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

  Univariate analysis Multivariate analysis
HR (95% CI) P HR (95% CI) P
Sex
 (Female/male) 1.061 (0.919–1.224) 0.420   
Age
 (< 60/≥ 60) 1.319 (0.987–1.763) 0.061   
Smoking status
 (Smoker/nonsmoker/unknown) 0.726 (0.518–1.018) 0.063   
Tumour status
 (Recurrence/initial IIIb–IV) 0.721 (0.560–0.926) 0.011 0.706 (0.548–0.909) 0.007
ECOG PS
 (0–1/2–4) 1.438 (0.872–2.372) 0.154   
Pathology
 (Non-adeno/adeno) 4.175 (2.113–8.250) 0.001 5.472 (2.623–11.417) 0.001
Timing of TKI
 (1/≥ 2) 0.643 (0.480–0.862) 0.003 0.610 (0.452–0.823) 0.001
EGFR mutation status
 (Compound/single) 1.883 (1.404–2.526) 0.001 1.981 (1.466–2.676) 0.001
TKI selection
 (Gefitinib/erlotinib/icotinib) 0.978 (0.819–1.167) 0.806   
  1. ECOG PS Eastern Cooperative Oncology Group performance status, HR hazard ratio, CI confidence interval
  2. All variables of different subgroups were compared with the single common mutation group; P < 0.05 was defined as significantly different